---
title: "Alaunos Therapeutics (TCRT) news: delisting and offering"
url: "https://aibio.space/companies/alaunos-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "TCRT delisting, offering and Nasdaq notice news: Alaunos Therapeutics gets Nasdaq delisting notice under $2,500,000 stockholders' equity rule."
---

TCRT Alaunos Therapeutics, Inc. NASDAQ · United States

# Alaunos Therapeutics (TCRT) news TCRT delisting, offering and Nasdaq notice news

Listings · 2026-10-21

## [Alaunos Therapeutics says $350.0 million financing restores Nasdaq equity compliance](https://aibio.space/news/alaunos-therapeutics-says-350-0-million-financing-restores-nasdaq/)

Alaunos told the SEC on October 21, 2026 that it believes its $350.0 million financing restored compliance with Nasdaq's $2,500,000 equity rule. The same filing says Nasdaq may not agree, and a November 10 hearing was still set.

## Latest Alaunos Therapeutics news

1. 2026-10-13 Mergers [Alaunos Therapeutics acquires Velaris, closes $350 million private placement](https://aibio.space/news/alaunos-therapeutics-acquires-velaris-closes-350-million-private/) Alaunos bought Velaris in a stock deal and closed a $350 million private placement led by Fairmount. Velaris has no product candidate tested in humans, and Alaunos had $124,000 in cash at June 30, 2026, according to its quarterly report.
2. 2026-10-09 Listings [Alaunos Therapeutics gets Nasdaq delisting notice under $2,500,000 stockholders' equity rule](https://aibio.space/news/alaunos-therapeutics-gets-nasdaq-delisting-notice-under-2-500-000/) Nasdaq staff told Alaunos on October 5, 2026 that its securities are subject to delisting under Listing Rule 5550(b)(1). The company plans to request a hearing and says it is working with a financial advisor on potential transactions.
3. 2026-09-18 Financings [Alaunos sells $1,120,000 of stock and warrants in registered direct offering](https://aibio.space/news/alaunos-sells-1-120-000-stock-warrants-registered-direct-offering/) Dawson James Securities is sole placement agent for the offering, priced at $1.46 per share under Nasdaq at-the-market rules.
4. 2026-09-16 Company Updates [Alaunos lowers stockholder meeting quorum to one-third of voting power](https://aibio.space/news/alaunos-lowers-stockholder-meeting-quorum-one-third-voting-power/) The board adopted Second Amended and Restated By-Laws on September 16, 2026, effective immediately.
5. 2026-06-29 Company Updates [Alaunos reports body-fat-adjusted liver weight analysis for ALN1003](https://aibio.space/news/alaunos-reports-body-fat-adjusted-liver-weight-analysis-aln1003/) Alaunos says a body-fat-adjusted analysis of liver weight in a 48-day mouse study supports further preclinical work on ALN1003.
6. 2026-05-26 Company Updates [Alaunos combines two ALN1003 mouse studies into one preclinical readout](https://aibio.space/news/alaunos-combines-two-aln1003-mouse-studies-one-preclinical-readout/) Alaunos says early, non-GLP mouse data for ALN1003 span weight, insulin resistance, adipose signaling and liver pathology.
7. 2026-05-18 Company Updates [Alaunos reports updated ALN1003 mouse data on insulin and liver markers](https://aibio.space/news/alaunos-reports-updated-aln1003-mouse-data-insulin-liver-markers/) Alaunos reported non-GLP mouse data for ALN1003 on insulin resistance, adipose signaling and liver histology, and said its cash runway extends into the second quarter of 2026.
8. 2026-04-09 Listings [Alaunos receives Nasdaq notice on stockholders' equity requirement](https://aibio.space/news/alaunos-receives-nasdaq-notice-stockholders-equity-requirement/) Nasdaq says Alaunos does not meet its $2,500,000 minimum for stockholders' equity, and the company plans to submit a compliance plan.
9. 2025-07-02 Listings [Alaunos Therapeutics tells Nasdaq it falls short of audit committee rule after CEO change](https://aibio.space/news/alaunos-therapeutics-tells-nasdaq-falls-short-audit-committee-rule/) Alaunos told Nasdaq on July 2, 2025 that its audit committee falls short of Listing Rule 5605(c). The shortfall came after chief executive Dale Curtis Hogue, Jr. resigned and director Holger Weis took over as CEO and left the committee. The company plans to use a 180-day grace period.

## Alaunos Therapeutics at a glance

- **Ticker**: TCRT

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $124,000

### Related companies

- [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) NASDAQ: GANX
- [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) NASDAQ: GLSI
- [Odyssey Therapeutics](https://aibio.space/companies/odyssey-therapeutics/) NASDAQ: ODTX
- [Scribe Therapeutics](https://aibio.space/companies/scribe-therapeutics/) NASDAQ: SCTX
- [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) NASDAQ: IAM
- [Equillium](https://aibio.space/companies/equillium/) NASDAQ: EQ
- [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) NASDAQ: KYTX
- [Instil Bio](https://aibio.space/companies/instil-bio/) NASDAQ: TIL

### Also on NASDAQ

- [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) LRMR
- [Rezolute](https://aibio.space/companies/rezolute/) RZLT
- [NewcelX](https://aibio.space/companies/newcelx/) NCEL
- [QTREX Quantum](https://aibio.space/companies/qtrex-quantum/) QTEX
- [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) BMEA
- [Autonomix Medical](https://aibio.space/companies/autonomix-medical/) AMIX

## Alaunos Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/) | [$362,000](https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/) |
| Net income (loss) | [-$4.2 million](https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/) | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/) |
| Cash from operations | [-$2.9 million](https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/) | [-$5.0 million](https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/) |
| Cash and equivalents | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1107421/000119312526352421/) | [$1.1 million](https://www.sec.gov/Archives/edgar/data/1107421/000119312526134720/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $124,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Alaunos Therapeutics

Was Alaunos Therapeutics delisted?

Our latest story on this, dated Oct 9, 2026: "Alaunos Therapeutics gets Nasdaq delisting notice under $2,500,000 stockholders' equity rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alaunos-therapeutics-gets-nasdaq-delisting-notice-under-2-500-000/).

Has Alaunos Therapeutics raised money recently?

Our latest story on this, dated Oct 13, 2026: "Alaunos Therapeutics acquires Velaris, closes $350 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alaunos-therapeutics-acquires-velaris-closes-350-million-private/).

Has Alaunos Therapeutics received a Nasdaq deficiency notice?

Our latest story on this, dated Apr 9, 2026: "Alaunos receives Nasdaq notice on stockholders' equity requirement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/alaunos-receives-nasdaq-notice-stockholders-equity-requirement/).

What is the ticker symbol of Alaunos Therapeutics?

Alaunos Therapeutics, Inc. trades under the ticker TCRT on NASDAQ.

Where is Alaunos Therapeutics listed?

Alaunos Therapeutics, Inc. is listed on NASDAQ.

What is the SEC CIK of Alaunos Therapeutics?

The SEC Central Index Key (CIK) for Alaunos Therapeutics, Inc. is 1107421. Its filings are on SEC EDGAR.

How many shares does Alaunos Therapeutics have outstanding?

2,540,480 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is Alaunos Therapeutics listed under?

Our directory records Alaunos Therapeutics, Inc. under United States.

What does Alaunos Therapeutics do?

Our directory classifies Alaunos Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Alaunos Therapeutics?

The ISIN recorded for Alaunos Therapeutics, Inc. is US98973P3091.

Does aibio.space cover Alaunos Therapeutics?

aibio.space lists Alaunos Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Alaunos Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

Is Alaunos Therapeutics profitable?

Alaunos Therapeutics, Inc. reported a net loss of $4.2 million for the fiscal year ended Dec 31, 2025, and used $2.9 million of cash in operations, per its annual report to the SEC.

How much does Alaunos Therapeutics spend on research and development?

$1.4 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Alaunos Therapeutics have?

$124,000 in cash at Jun 30, 2026, per its 10-Q.

## Investor discussion: Alaunos Therapeutics

Members talk about Alaunos Therapeutics (TCRT). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Alaunos Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-10-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000119312526427890/tcrt-20261021.htm)
2. 2026-10-13 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000119312526419829/tcrt-ex99_1.htm)
3. 2026-10-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000119312526419154/tcrt-20261005.htm)
4. 2026-04-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000119312526157126/tcrt-20260409.htm)
5. 2026-01-08 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,3.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000119312526007054/tcrt-20260108.htm)
6. 2025-08-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000095017025110484/tcrt-20250819.htm)
7. 2025-07-10 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000095017025095029/tcrt-20250703.htm)
8. 2025-07-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000095017025093263/tcrt-20250701.htm)
9. 2025-06-10 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000095017025083913/tcrt-20250609.htm)
10. 2025-05-23 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000095017025077064/tcrt-20250519.htm)
11. 2025-05-21 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1107421/000119312525123677/d921291ddef14a.htm)
12. 2025-05-09 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1107421/000119312525116509/d921291dpre14a.htm)
13. 2025-04-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1107421/000095017025053325/tcrt-20250407.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TCRT on TradingView](https://www.tradingview.com/symbols/NASDAQ-TCRT/).

## SEC filings and registration

- **SEC name**: Alaunos Therapeutics, Inc.

- **CIK**: 1107421

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: TCRT (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 501 E LAS OLAS BLVD, FORT LAUDERDALE, FL, 33301

- **Phone**: (346) 355-4099

- **Shares outstanding**: 2,540,480 as of 2026-08-14 (10-Q filed 2026-08-14)

- **Former names**: ZIOPHARM ONCOLOGY INC; EASYWEB INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1107421/000119312526427890/tcrt-20261021.htm) filed 2026-10-21
- [8-K](https://www.sec.gov/Archives/edgar/data/1107421/000119312526419829/tcrt-20261013.htm) filed 2026-10-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1107421/000119312526419154/tcrt-20261005.htm) filed 2026-10-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1107421/000119312526397996/tcrt-20260918.htm) filed 2026-09-22
- [8-K](https://www.sec.gov/Archives/edgar/data/1107421/000119312526393462/tcrt-20260916.htm) filed 2026-09-17
- [10-Q](https://www.sec.gov/Archives/edgar/data/1107421/000119312526352421/tcrt-20260630.htm) filed 2026-08-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1107421/000119312526286914/tcrt-20260629.htm) filed 2026-06-29
- [8-K](https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/tcrt-20260526.htm) filed 2026-05-26

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001107421), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Alaunos Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TCRT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Alaunos Therapeutics, Inc.

- **Ticker**: TCRT

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US98973P3091

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TCRT/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/alaunos-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alaunos Therapeutics (TCRT) news: delisting and offering", 2026-10-31, https://aibio.space/companies/alaunos-therapeutics/